If you’ve ever looked at a hospital bill and felt your heart sink — wondering how you’ll afford the treatment that could save your life — then this isn’t about numbers. It’s about whether you get to choose treatment at all.
When you hear the words “you have cancer,” your mind races through a thousand questions. But for patients in the United States, the United Kingdom, Canada, France, and across the Middle East, one question surfaces almost immediately: Can I afford the treatment?
This article is not about choosing between treatment and no treatment. It is about showing you that there is a third option — one that thousands of international patients have already taken. We will walk you through the real numbers, the real hospitals, and the real savings of receiving cancer treatment in China, so you can make an informed decision for yourself or someone you love.
The Cost Crisis in Western Cancer Care
United States
The United States spends more on healthcare than any other nation — $4.5 trillion in 2024, or 17.3% of GDP. Yet cancer patients face extraordinary financial burden.
United States
According to the American Cancer Society, the average cost of cancer care in the US in the first year after diagnosis is:
| Cost Component | Average Cost (USD) |
|---|---|
| Initial diagnosis and staging | $5,000-15,000 |
| Surgery | $20,000-80,000 |
| Chemotherapy (first year) | $30,000-100,000 |
| Radiation therapy | $10,000-50,000 |
| Targeted therapy (first year) | $50,000-150,000 |
| Hospitalization | $10,000-50,000 |
| Emergency room visits | $2,000-10,000 |
| Total first year (average) | $42,000 out-of-pocket; $150,000+ total |
Sources: American Cancer Society (2025), Milliman Medical Index (2025), Kaiser Family Foundation (2025).
Even with insurance, the burden is crushing. A 2025 study in JAMA Oncology found that 42% of cancer patients depleted their life savings within two years of diagnosis. Medical bankruptcy is the leading cause of bankruptcy in the United States.
United Kingdom
The NHS provides cancer care free at the point of use, but the “cost” comes in time rather than money. The 62-day target from urgent GP referral to first treatment has not been met since 2015. In February 2026, only 68.6% of patients met this target.
For patients who choose private treatment in the UK — often to bypass waiting lists — the costs are substantial:
| Treatment | NHS | UK Private (USD) |
|---|---|---|
| Initial oncology consultation | Free (wait 2-8 weeks) | $250-500 |
| PET-CT scan | Free (wait 2-6 weeks) | $1,500-3,000 |
| Chemotherapy (per cycle) | Free | $5,000-10,000 |
| Immunotherapy (per cycle) | Free (subject to NICE approval) | $8,000-15,000 |
| Breast cancer surgery | Free | $10,000-20,000 |
| Radiation therapy (30 fractions) | Free | $8,000-15,000 |
Source: UK Private Healthcare data (2025-2026), NHS cancer waiting times data.
Canada
Canada’s public system also system keeps treatment costs low for patients, but the wait times are the longest in the developed world. The Fraser Institute’s 2024 report found the median wait from GP referral to see from GP referral to treatment was 30.0 weeks- the longest ever measured.
For patients who go private in Canada (limited availability) or in private US hospitals:
| Treatment | Canada Public | Canada/US Private (USD) |
|---|---|---|
| Oncology consultation | Free (wait 4-12 weeks) | $500-1,500 |
| PET-CT scan | Free (wait 4-12 weeks) | $2,000-4,000 |
| Chemotherapy (per cycle) | Free | $6,000-12,000 |
| Immunotherapy (per cycle) | Free | $10,000-18,000 |
| Lung cancer surgery | Free | $25,000-50,000 |
China Cost Breakdown: Procedure by Procedure
Now let’s look at what the same treatments cost in China’s top cancer centers.
Diagnostic Imaging
| Procedure | China (USD) | US (USD) | UK Private (USD) | Savings vs. US |
|---|---|---|---|---|
| PET-CT (whole body) | $500-900 | $3,000-5,000 | $1,500-3,000 | 80-88% |
| MRI (with contrast) | $70-150 | $1,000-2,500 | $500-1,000 | 90-97% |
| CT scan (chest/abdomen/pelvis) | $50-120 | $500-2,000 | $300-600 | 88-97% |
| Ultrasound | $20-50 | $200-1,000 | $100-300 | 90-95% |
| Biopsy (CT-guided) | $200-500 | $2,000-5,000 | $1,000-2,500 | 85-90% |
| Pathology review (IHC) | $100-300 | $500-2,000 | $300-800 | 70-85% |
| Genetic sequencing (panel) | $500-1,500 | $3,000-10,000 | $2,000-5,000 | 70-85% |
| Genetic sequencing (WES/WGS) | $1,000-3,000 | $5,000-15,000 | $3,000-8,000 | 70-80% |
Systemic Therapy
| Therapy | China per Cycle (USD) | US per Cycle (USD) | UK Private per Cycle (USD) | Savings vs. US |
|---|---|---|---|---|
| Chemotherapy (standard platinum doublet) | $200-600 | $5,000-15,000 | $3,000-8,000 | 85-96% |
| Chemotherapy (taxane) | $400-800 | $8,000-20,000 | $4,000-10,000 | 90-96% |
| PD-1 inhibitor (domestic, e.g., sintilimab) | $1,500-3,000 | N/A (not approved) | N/A | China-only option |
| PD-1 inhibitor (imported, e.g., Keytruda) | $3,000-6,000 | $15,000-25,000 | $8,000-15,000 | 75-85% |
| Herceptin (trastuzumab, domestic biosimilar) | $400-800 | $8,000-12,000 | $5,000-8,000 | 90-95% |
| Herceptin (imported) | $1,500-3,000 | $8,000-12,000 | $5,000-8,000 | 70-85% |
| Targeted therapy (TKI, domestic) | $1,000-2,000 | $10,000-20,000 | $5,000-12,000 | 88% |
| CAR-T (total therapy, including hospitalization) | $50,000-80,000 | $370,000-475,000 | $300,000-400,000 | 80-87% |
Radiation Therapy
| Type | China (USD) | US (USD) | UK Private (USD) | Savings |
|---|---|---|---|---|
| IMRT (30 fractions) | $4,000-8,000 | $30,000-70,000 | $12,000-12,000-36,000 | $12,000-25,000 |
| SBRT/SRS (1-5 fractions) | $3,000-6,000 | $15,000-40,000 | $8,000-20,000 | 80-85% |
| Proton therapy (full course) | $300,000 | $60,000-150,000 | $50,000-100,000 | 50-67% |
| Carbon ion therapy (full course) | $40,000-70,000 | $100,000-200,000 (limited availability) | Limited | 60-65% |
Surgery
| Procedure | China (USD) | US (USD) | UK Private (USD) | Savings |
|---|---|---|---|---|
| Breast lumpectomy | $3,000-6,000 | $15,000-30,000 | $8,000-15,000 | 75-80% |
| Mastectomy with reconstruction | $8,000-14,000 | $40,000-800,000 | $20,000-40,000 | 75-85% |
| Lung lobectomy (VATS) | $8,000-15,000 | $30,000-60,000 | $15,000-30,000 | 70-80% |
| Colectomy (laparoscopic) | $8,000-15,000 | $30,000-70,000 | $15,000-30,000 | 70-80% |
| Hepatobiliary surgery (complex) | $15,000-30,000 | $60,000-150,000 | $30,000-60,000 | 75-85% |
| Gastrectomy | $10,000-18,000 | $40,000-100,000 | $20,000-40,000 | 75-85% |
| Robotic-assisted (da Vinci) surgery | $12,000-22,000 | $50,000-120,000 | $25,000-50,000 | 72-85% |
Hospitalization & Supportive Care
| Item | China (USD per day) | US (USD per day) | UK Private (USD per day) | Savings |
|---|---|---|---|---|
| Private room (international center) | $100-300 | $2,000-5,000 | $1,000-2,500 | 90-95% |
| Semi-private room | ||||
| Semi-private room | $50-100 | $1,500-3,500 | $500-1,500 | 90-97% |
| ICU (per day) | $300-800 | $5,000-15,000 | $2,000-5,000 | 85-95% |
| Anti-emetics (per cycle) | $10-30 | $200-500 | $100-300 | 90-95% |
| G-CSF (filgrastim, per cycle) | $50-150 | $500-2,000 | $300-800 | 85-92% |
| Blood transfusion (per unit) | $50-100 | $200-500 | $150-300 | 65-80% |
Real Patient Cost Comparison: Complete Treatment Packages
Breast Cancer (Stage II HER2+, 12-month treatment)
| Component | US (USD) | China (USD) |
|---|---|---|
| Neoadjuvant chemo (4 cycles TCHP) | $40,000-60,000 | $3,500-6,000 |
| Surgery (mastectomy + reconstruction) | $50,000-80,000 | $8,000-14,000 |
| Herceptin (18 cycles) | $60,000-90,000 | $8,100 (biosimilar) |
| Radiation (30 fractions) | $30,000-50,000 | $4,000-7,000 |
| Follow-up (12 months) | $10,000-20,000 | $1,500-3,000 |
| Total (medical only) | $190,000-300,000 | $25,100-38,100 |
| Flights + accommodation + concierge (12 months) | N/A | $10,000-20,000 |
| Grand Total | $190,000-300,000 | $35,100-58,100 |
| Savings with Travel | $132,000-265,000 |
Lung Cancer (Stage IV NSCLC, 6 months treatment)
| Component | US (USD) | China (USD) |
|---|---|---|
| PD-1 inhibitor (6 cycles) | $90,000-150,000 | $9,000-18,000 (domestic) |
| Chemotherapy (6 cycles, platinum doublet) | $30,000-60,000 | $1,200-3,600 |
| PET-CT (2 scansa(2) | $6,000-10,000 | $1,000-1,800 |
| CT scans (4) | $2,000-4,000 | $200-480 |
| Supportive medications | $6,000-12,000 | $400-800 |
| Specialist consultations | $4,000-8,000 | $500-1,000 |
| Total (medical only) | $138,000-244,000 | $12,300-25,680 |
| Flights + accommodation + concierge (6 months) | N/A | $8,000-15,000 |
| Grand Total | $138,000-244,000 | $20,300-40,680 |
| Savings with Travel | $97,300-223,320 |
Colorectal Cancer (Stage III, 6 months treatment)
| Component | US (USD) | China (USD) |
|---|---|---|
| Surgery (laparoscopic colectomy) | $30,000-60,000 | $8,000-15,000 |
| Chemotherapy (FOLFOX, 8 cycles) | $40,000-80,000 | $1,600-4,800 |
| Imaging (CTs, MRI) | $4,000-8,000 | $400-800 |
| Ostomy care (if needed) | $3,000-6,000 | $400-800 |
| Follow-up (6 months) | $5,000-10,000 | $800-12,000 |
| Total (medical only) | $82,000-164,000 | $11,200-23,400 |
| Travel + accommodation | N/A | $6,000-12,000 |
| Grand Total | $82,000-164,000 | $17,200-35,400 |
| Savings | $64,800-128,600 |
Why Are Cancer Costs So Much Lower in China?
Factor 1: Drug Pricing
Domestic pharmaceutical companies produce generics and biosimilars at prices that are 70-95% below original branded products in Western markets. Examples:
| Drug | US Brand Price | China Domestic Price | Savings |
|---|---|---|---|
| Trastuzumab (Herceptin) | $8,000-12,000/cycle | $400-800/cycle (domestic biosimilar) | 90-95% |
| Rituximab (Rituxan) | $6,000-10,000/cycle | $400-800/cycle (biosimilar) | 90-92% |
| Bevacizumab (Avastin) | $5,000-8,000/cycle | $300-600/cycle (biosimilar) | 90-94% |
| Pembrolizumab (Keytruda) | $15,000-25,000/cycle | $3,000-6,000/cycle (imported) | 75-85% |
| Sintilimab (PD-1 domestic) | N/A | $1,500-3,000/cycle | China-only |
| Osimertinib (Tagrisso) | $15,000-20,000/month | $3,000-5,000/month (imported) | 70-85% |
| Icotinib (EGFR TKI domestic) | N/A | $800-1,500/month | China-only |
Factor 2: Hospital Operational Costs
Chinese hospitals operate on significantly lower margins than Western hospitals. A major cancer center in China operates at 70-80% lower cost per patient bed than its US counterpart — due to lower physician salaries, lower administrative costs, and much lower malpractice insurance premiums.
Factor 3: Government Price Controls
The Chinese government caps markups on medications and procedures. China’s Volume-Based Procurement (VBP) program has reduced drug prices by an average of 50% or more for included medications.
Factor 4: High Volume
China’s top cancer centers see 5-10 times more patients per day than Western centers. This high volume spreads fixed costs over far more procedures, reducing the cost per patient.
The “Hidden” Costs: What You Need to Budget Beyond the Procedure
When planning your budget for cancer treatment in China, you need to account for:
| Expense | Estimated Range (USD) |
|---|---|
| Flights (round trip) | $1,000-3,000 (North America/Europe) |
| Accommodation (per month) | $800-5,000 per month (depending on city and type) |
| Daily living expenses | $30-60 per person per day |
| Travel insurance (cancer-specific) | $100-500 for trip duration |
| myMedVia Fast-track Access | $300 |
| myMedVia Full Concierge | $1,000+ |
| Emergency fund (unforeseen medical needs) | $3,000-5,000 recommended |
Typical total budget for 6-week treatment trip: $15,000-35,000 all-inclusive (medical + travel).
Insurance for International Patients
Can I use my health insurance in China?
Many international health insurance plans cover treatment in China. However, coverage varies significantly require you to pay upfront and claim reimbursement. Check with your provider:
Does your plan cover treatment at overseas medical facilities?Does China require pre-authorization? majorWhat is the claims reimbursement process?Does your provider have direct billing arrangements with any Chinese hospitals?Insurance companies with direct billing in China: – AXA – Cigna – Allianz – BUPA – Aetna – Now Health – MSH International – GeoBlue – April International
Payment methods
| Method | Details |
|---|---|
| Cash | Accepted at all hospitals (USD, EUR:000, Yuan) |
| Credit card | Visa, Mastercard, Amex widely accepted at international centers |
| Bank transfer | Common for larger treatment deposits |
| Direct billing | Must be confirmed before treatment |
Tax benefits: In some countries (notably the US), medical expenses including travel for treatment may be tax-deductible. Consult your tax advisor.
How myMedVia Ensures Cost Transparency
Fast-track Access ($300): – Medical record review and cost estimation within 48 hours – Hospital matching based on your diagnosis – Priority appointment scheduling – Medical visa invitation letter
Full Concierge ($1,000): – Everything in Fast-track plus: – Airport pickup and accommodation booking – In-person interpretation during appointments – Dedicated patient coordinator – Post-treatment follow-up and telemedicine coordination
All cost estimates provided by our partner hospitals are itemized and transparent. We do not add hidden markups.
The Bottom Line
Cancer treatment in China is not “cheaper” in the sense of being lower quality — it is fundamentally more affordable due to structural differences in how healthcare is priced. The savings are real, documented, and life-changing.
A patient from the US facing a $200,000 treatment bill can expect to pay $30,000-60,000 for the same care in China, including travel and accommodation. A patient from the UK or Canada facing a 6-12 month wait can access treatment within 2-3 weeks.
The decision to travel for cancer treatment is deeply personal. But the math is clear: for most patients, the combination of cost savings, faster access, and high-quality care makes China a compelling option.
Want to know exactly how much your specific case would save? Submit your medical records and get a free cost estimate and personalized treatment plan within 48 hours. Contact myMedVia → mymedvia.com
Fast · Affordable · Certain
